Canine Vomiting: Diagnostic Approach for Pancreatitis

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Vomiting in dogs is a common presentation where pancreatitis is a significant differential diagnosis, necessitating a systematic approach integrating signalment, history, physical examination, and diagnostic testing. Key historical indicators include middle-aged to older dogs, breeds predisposed to pancreatitis, and recent dietary indiscretion or high-fat meals.
• The diagnostic workup for suspected canine pancreatitis relies on a multi-modal strategy, prioritizing serum canine pancreatic lipase immunoreactivity (cPLI) as the most sensitive single blood test, interpreted alongside a minimum database (CBC, biochemistry, electrolytes, venous blood gas) and abdominal ultrasonography. Traditional serum amylase and lipase activities are considered unreliable due to poor specificity and sensitivity.
• Abdominal ultrasonography is the preferred imaging modality for pancreatitis, identifying characteristic findings such as pancreatic enlargement, hypoechoic parenchyma, and peripancreatic fat changes, though its sensitivity is operator-dependent and may miss mild cases. Abdominal radiography plays a secondary role, primarily for excluding gastrointestinal obstruction or foreign bodies.
• Pancreatitis in dogs can present with a spectrum of clinical severity, from mild transient vomiting to severe necrotizing disease with systemic inflammatory response syndrome (SIRS), necessitating concurrent disease screening for conditions like diabetic ketoacidosis, hyperadrenocorticism, and infectious causes such as Ehrlichia canis.
• Treatment of canine pancreatitis is primarily supportive, focusing on intravenous fluid therapy, aggressive analgesia with opioid analgesics, effective antiemetic therapy (e.g., maropitant), and early enteral nutritional support to maintain gut integrity. Serial monitoring of hydration, perfusion, pain scores, and organ function is critical for assessing severity and guiding therapeutic escalation.
• Diagnostic limitations exist, including potential false positives for cPLI in dogs with decreased glomerular filtration rate or concurrent ehrlichiosis, and the subjective nature of ultrasonographic findings. Advanced imaging like CT is reserved for complex cases or suspected complications such as abscess formation.

Vomiting is among the most common presenting complaints in canine practice, and pancreatitis sits high on the differential list for any dog with acute or recurrent emesis. This article provides a systematic diagnostic framework for the vomiting dog in which pancreatitis is suspected, from initial triage through confirmatory testing and early therapeutic decision-making. It is written for practicing veterinarians who need a practical, evidence-informed pathway that distinguishes pancreatic disease from the many other causes of vomiting while avoiding overdiagnosis and unnecessary intervention.

The approach rests on three pillars: recognizing that pancreatitis in dogs produces a spectrum of clinical severity, integrating laboratory and imaging findings instead of relying on any single test, and understanding that the diagnostic workup must proceed in parallel with supportive therapy. The clinical question this article answers is direct: when a dog vomits and pancreatitis is on the list, what tests should be run, in what order, and how should the results change management?

At a Glance

Pathophysiology of Canine Pancreatitis

The exocrine pancreas synthesises and secretes digestive enzymes as inactive zymogens. Pancreatitis begins when premature intracellular activation of these zymogens triggers autodigestion of pancreatic parenchyma. The resulting inflammatory cascade recruits neutrophils and macrophages, releases proinflammatory cytokines, and leads to local necrosis, peripancreatic fat saponification, and in severe cases, systemic inflammatory response syndrome. The inflammatory process also injures adjacent structures, including the duodenum and biliary tree, which explains why vomiting, instead of isolated abdominal pain, dominates the clinical picture.

Vomiting in pancreatitis arises from multiple mechanisms. Local inflammation irritates the duodenum and gastric wall, peritoneal irritation triggers visceral afferent signaling, and ileus develops as motility is suppressed. In severe disease, endotoxemia and circulating inflammatory mediators activate the chemoreceptor trigger zone and the vomiting center directly. This multifactorial origin means that antiemetic therapy must address both peripheral and central pathways, and that control of vomiting often lags behind resolution of the underlying pancreatic inflammation.

The severity spectrum matters clinically. Mild pancreatitis produces transient vomiting and abdominal discomfort that resolves with supportive care. Severe necrotising pancreatitis causes refractory vomiting, hypovolemic shock from third-space fluid losses, acute kidney injury, and disseminated intravascular coagulation. The diagnostic workup must therefore identify also whether pancreatitis is present but also how severe it is, because severity determines monitoring intensity and prognosis.

Diagnostic Limitations of Traditional Tests

Serum amylase and lipase activities have historically been used to diagnose canine pancreatitis, but their limitations are well documented. These enzymes are not pancreas-specific in dogs. Amylase is cleared by the kidneys, so azotemia elevates its activity independent of pancreatic disease. Lipase activity rises with glucocorticoid administration and with some non-pancreatic gastrointestinal diseases. Neither enzyme reliably distinguishes mild from severe pancreatitis, and both can be normal in dogs with confirmed disease. For these reasons, traditional enzyme activities serve as screening tests at best, and a normal result does not exclude pancreatitis.

The development of canine pancreatic lipase immunoreactivity (cPLI) represented a substantive advance. This immunoassay measures the concentration of pancreas-specific lipase instead of total enzymatic activity, giving it superior specificity for pancreatic origin. The assay is commercially available and can be run on serum samples without special handling. Serial measurement has been used to monitor disease progression, although the optimal frequency of re-testing is not firmly established. As with any diagnostic test, cPLI results must be interpreted in the clinical context, because the assay detects pancreatic inflammation but does not quantify its severity or predict complications.

Infectious and Concurrent Disease Considerations

Pancreatitis in dogs is not always a primary pancreatic disorder. Systemic infections can secondarily involve the pancreas, and the diagnostic workup should consider this possibility in endemic regions or when atypical features are present. Canine monocytic ehrlichiosis, caused by Ehrlichia canis, is one such example. In a study of naturally infected dogs, approximately 20% showed serum cPLI concentrations in the diagnostic range for pancreatitis, and this occurred in dogs without gastrointestinal signs. The clinical implication is that a dog with confirmed ehrlichiosis and elevated cPLI may not have primary pancreatitis, and conversely, a dog presenting with vomiting and elevated cPLI in an endemic area should be evaluated for concurrent tick-borne disease. The published investigation of cPLI in canine monocytic ehrlichiosis documents this association and supports including infectious disease screening in the diagnostic plan for dogs with risk factors.

Other concurrent conditions complicate the picture. Diabetic ketoacidosis can cause vomiting and is associated with pancreatitis, either as a trigger or a consequence. Hyperadrenocorticism predisposes dogs to pancreatitis through chronic glucocorticoid excess. Hepatic disease, particularly cholangiohepatitis, can produce vomiting and may coexist with pancreatic inflammation given the shared biliary drainage. The diagnostic approach must therefore include a minimum database that screens for these comorbidities instead of focusing exclusively on the pancreas.

The Role of Imaging

Abdominal ultrasonography is the imaging modality of choice when pancreatitis is suspected. The ACVIM consensus statements on gastrointestinal and pancreatic disease provide expert guidance on the use of imaging in this context. Ultrasonographic findings supportive of pancreatitis include pancreatic enlargement, hypoechoic parenchyma relative to surrounding mesentery, hyperechoic peripancreatic fat indicating saponification, and peritoneal effusion. The sensitivity of ultrasonography is operator-dependent and higher in severe disease, so a normal study does not exclude mild pancreatitis. Conversely, ultrasonography can identify alternative causes of vomiting, including gastrointestinal foreign bodies, intussusception, and mass lesions, which makes it valuable even when the index of suspicion for pancreatitis is high.

Abdominal radiography has a limited but defined role. It cannot visualize the pancreas directly in most dogs, but it can exclude mechanical obstruction, identify radiopaque foreign bodies, and reveal loss of serosal detail that suggests peritonitis or effusion. Radiographs are most useful early in the workup, before ultrasonography, to triage surgical versus medical causes of vomiting. The MSD Veterinary Manual provides a systematic overview of imaging findings in canine gastrointestinal disease that supports this staged approach.

Integrating the Diagnostic Plan

The diagnostic workup proceeds in stages. The first stage is stabilization and triage: assess hydration, perfusion, and pain, and begin intravenous fluid therapy before diagnostic testing is complete. The second stage is the minimum database: complete blood count, biochemistry panel, electrolytes, and venous blood gas. This identifies azotemia, electrolyte derangements such as hypokalemia, and acid-base abnormalities that require correction. The third stage is pancreatic-specific testing with cPLI, interpreted alongside the minimum database. The fourth stage is imaging, with ultrasonography preferred when available. The fifth stage is screening for concurrent disease, including infectious disease testing when epidemiologically appropriate.

This staged approach recognizes that pancreatitis is a clinical diagnosis supported by laboratory and imaging findings, not a diagnosis made by any single test. It also acknowledges that treatment must begin before the diagnostic workup is complete, because delays in fluid resuscitation and pain control worsen outcomes in severe disease. The remaining sections of this article detail each stage of the workup, the interpretation of specific test results, and the therapeutic decisions that follow.

Diagnostic Testing Sequence and Interpretation

The diagnostic workup for suspected pancreatitis in a vomiting dog should proceed in a logical sequence that balances diagnostic yield, cost, and patient stability. Begin with a minimum database, then progress to pancreatic-specific testing, and finally imaging when the diagnosis remains uncertain or complications are suspected.

Minimum Database and Its Limitations

A complete blood count, serum biochemistry profile, and urinalysis should be performed in every vomiting dog with suspected pancreatitis. These tests serve three purposes: they support the pancreatitis diagnosis, they identify concurrent disease that may complicate management, and they establish baseline values for monitoring.

The CBC may reveal a stress leukogram or, less commonly, an inflammatory leukocytosis with a left shift. Biochemistry abnormalities are nonspecific but frequently include elevations in alanine aminotransferase and alkaline phosphatase, reflecting reactive hepatic inflammation or concurrent biliary disease. Azotemia may indicate prerenal dehydration or primary renal disease. Hyperbilirubinemia suggests extrahepatic bile duct obstruction or severe hepatic involvement. Hyperglycemia can result from stress, but persistent hyperglycemia in a dog with pancreatitis carries prognostic significance and warrants monitoring for diabetes mellitus.

Serum amylase and lipase activities are poorly sensitive and poorly specific for canine pancreatitis. They may be normal in confirmed disease and elevated in dogs with renal failure, gastrointestinal disease, or hepatic disease. These tests should not be used as the sole laboratory basis for diagnosis or exclusion of pancreatitis.

Pancreatic Lipase Immunoreactivity

Serum canine pancreatic lipase immunoreactivity (cPLI) is the most accurate commercially available blood test for diagnosing pancreatitis in dogs. The test measures pancreatic lipase specifically, avoiding the cross-reactivity that limits traditional lipase assays. A cPLI concentration below 200 μg/L makes pancreatitis unlikely. Values between 200 and 400 μg/L are considered equivocal and warrant repeat testing or additional diagnostic evaluation. Concentrations above 400 μg/L support a diagnosis of pancreatitis when combined with compatible clinical signs.

Interpret cPLI results with attention to the clinical context. The test can be falsely elevated in dogs with decreased glomerular filtration rate, because pancreatic lipase is cleared renally. Dogs with chronic kidney disease may therefore have cPLI concentrations in the diagnostic range without clinical pancreatitis. Conversely, cPLI may be normal early in the course of acute disease, so a single normal result does not exclude pancreatitis if clinical suspicion remains high.

Infectious disease can confound cPLI interpretation. A study of dogs with naturally occurring monocytic ehrlichiosis found that 20% had serum cPLI concentrations above 400 μg/L in the absence of gastrointestinal signs, suggesting that serum pancreatic lipase immunoreactivity in canine monocytic ehrlichiosis may be elevated as part of systemic infectious disease. In endemic regions, consider tick-borne disease testing in dogs with elevated cPLI and atypical clinical features.

Abdominal Ultrasonography

Ultrasonography complements laboratory testing and is particularly valuable when the diagnosis is uncertain, when the patient is not improving, or when concurrent biliary or gastrointestinal disease is suspected. Sonographic findings supportive of pancreatitis include an enlarged, hypoechoic pancreas with hyperechoic surrounding mesentery, which reflects peripancreatic fat necrosis and inflammation. The pancreas may appear irregular in outline, and the surrounding mesentery may show increased echogenicity. Peritoneal effusion, when present, is typically a modified transudate or exudate.

Ultrasonography also permits evaluation of the biliary tree, liver, stomach, duodenum, and mesenteric lymph nodes. This is essential because vomiting in dogs frequently has multiple contributing causes, and feline exocrine pancreatic disorders demonstrate that pancreatic disease often coexists with inflammatory disease of the liver and intestines. The same principle applies in dogs. A normal pancreatic ultrasound does not exclude mild pancreatitis, and the sensitivity of ultrasonography for detecting pancreatitis is operator dependent. When available, the combination of cPLI and ultrasonography provides the highest diagnostic confidence.

When to Pursue Advanced Imaging

Computed tomography with contrast enhancement can identify pancreatic enlargement, peripancreatic fat stranding, and complications such as abscess formation or pseudocysts. CT is more sensitive than ultrasonography for detecting peripancreatic inflammation in some cases, but it requires general anesthesia or heavy sedation, which may be poorly tolerated in a vomiting, hemodynamically unstable patient. Reserve CT for cases where ultrasonography is inconclusive, where a pancreatic mass or abscess is suspected, or where surgical intervention is being considered.

Treatment Protocol and Monitoring

Treatment of pancreatitis in dogs is primarily supportive. No specific therapy reverses pancreatic inflammation, so the goals are to restore and maintain perfusion, control pain and vomiting, provide nutritional support, and monitor for and treat systemic complications.

Fluid Therapy and Electrolyte Management

Intravenous crystalloid therapy is the foundation of treatment. Vomiting dogs are frequently dehydrated and may have ongoing losses. Calculate the fluid deficit, estimate maintenance requirements, and add estimated ongoing losses. Replace deficits over 12 to 24 hours, then adjust the rate based on serial assessments of hydration status, urine output, and body weight. Monitor packed cell volume, total protein, and electrolyte concentrations at least daily during the initial stabilization period.

Potassium abnormalities are common. Vomiting causes loss of hydrogen ions and chloride, leading to hypochloremic metabolic alkalosis, but concurrent anorexia and stress can produce metabolic acidosis. Potassium depletion is frequent because of gastrointestinal losses and decreased intake. Supplement potassium based on measured serum concentrations and current formulary guidelines. Hypokalemia can worsen ileus and contribute to weakness. Hypocalcemia, when present, may reflect saponification of peripancreatic fat and carries a guarded prognosis.

Analgesia and Antiemetic Therapy

Abdominal pain is a consistent feature of pancreatitis in dogs and should be treated aggressively. Opioid analgesics are the mainstay. Choose an agent based on patient status, pain severity, and formulary availability. Reassess pain scores at regular intervals and adjust therapy accordingly.

Antiemetic therapy is indicated for dogs with persistent vomiting. Metoclopramide, a dopamine antagonist, is commonly used but may be less effective in severe cases. Maropitant, a neurokinin-1 receptor antagonist, acts centrally and peripherally and is often more effective for vomiting associated with visceral inflammation. Ondansetron, a 5-HT3 antagonist, can be added for refractory vomiting. Combine antiemetic therapy with acid suppression using a proton pump inhibitor or histamine-2 receptor antagonist if gastritis or esophagitis is suspected.

Nutritional Support

Early enteral nutrition is associated with improved outcomes in canine pancreatitis. Historically, fasting was recommended to rest the pancreas, but current evidence supports early feeding to maintain gut barrier integrity and reduce the risk of bacterial translocation. Offer small, frequent meals of a highly digestible, low-fat diet once vomiting is controlled. If the dog refuses food for more than 24 to 48 hours, place a nasoesophageal or esophagostomy tube and begin assisted feeding. Total parenteral nutrition is reserved for dogs that cannot tolerate enteral feeding, and it carries higher risks of catheter-related sepsis and metabolic complications.

Monitoring Parameters and Complication Surveillance

Monitor for systemic complications including disseminated intravascular coagulation, acute kidney injury, respiratory distress from aspiration pneumonia or acute respiratory distress syndrome, and sepsis. A rising fever, worsening leukocytosis, or deteriorating mentation should prompt investigation for pancreatic abscess or infected necrosis. These complications may require surgical debridement or drainage and carry a guarded prognosis.

Adjusting Therapy Based on Response

Reassess the patient at least twice daily during the acute phase. Improvement is marked by reduced vomiting, resolution of abdominal pain, and a return of appetite. Taper analgesic and antiemetic therapy gradually as clinical signs resolve. Dogs that fail to improve within 48 to 72 hours of supportive therapy warrant repeat imaging and reconsideration of the diagnosis. Consider concurrent disease such as gastrointestinal foreign body, perforation, or inflammatory bowel disease, and revisit infectious differentials in endemic areas.

The MSD Veterinary Manual provides additional detail on supportive care protocols and complication management for acute pancreatitis. For dogs with recurrent or chronic pancreatitis, address underlying predisposing factors such as hyperlipidemia, dietary indiscretion, and drug exposure. Long-term management focuses on a consistent low-fat diet, avoidance of trigger foods, and periodic monitoring of pancreatic enzyme activity and metabolic parameters.

Recognized Complications and Early Detection

Pancreatitis in dogs follows a clinical course that can deteriorate rapidly, and the clinician's primary task is to recognize decompensation before it becomes irreversible. Systemic inflammatory response syndrome is the most consequential complication. It is detected early by trending heart rate, respiratory rate, and temperature at four to six hour intervals, with particular attention to tachypnoea or progressive tachycardia that is not explained by pain or hypovolemia alone. Hypotension, defined as a systolic blood pressure below 90 mmHg, warrants immediate intervention.

Acute kidney injury develops from hypovolemia, hypotension, or systemic inflammation. Serial measurement of creatinine and symmetric dimethylarginine, alongside urine output estimation, identifies early decline. Oliguria in a dog that has received adequate fluid resuscitation is a red flag. Hepatic injury, manifesting as increasing alanine aminotransferase and bilirubin, may reflect bile duct compression from pancreatic inflammation or systemic hypoperfusion. Coagulopathy, including disseminated intravascular coagulation, is detected by prolonged clotting times, thrombocytopenia, and elevated D-dimer concentrations. Serial platelet counts are inexpensive and often the first clue.

Pulmonary complications include aspiration pneumonia and acute respiratory distress syndrome. Crackles on auscultation, increased respiratory effort, or declining pulse oximetry readings should prompt thoracic radiography. Hyperglycemia from beta-cell damage or insulin resistance is common and usually transient, but persistent hyperglycemia with ketonuria indicates diabetic ketoacidosis requiring insulin therapy. Hypocalcemia, when ionised calcium falls below 1.0 mmol/L, is associated with more severe disease and may require supplementation.

Common Diagnostic Errors and Corrective Actions

The most frequent error is anchoring on a single positive cPLI result without considering the pretest probability. A dog with vomiting and a mildly elevated cPLI may have inflammatory bowel disease, not pancreatitis, and the distinction matters for therapy. The corrective action is to interpret cPLI in the context of the full minimum database and ultrasonographic findings.

A second error is dismissing a normal cPLI in a dog with strong clinical suspicion. Sensitivity of cPLI is imperfect, and early disease or chronic pancreatitis may produce values below the decision threshold. Repeat testing at 24 to 48 hours, or proceeding to ultrasonography, is more useful than abandoning the diagnosis.

A third error is overinterpreting ultrasonographic findings. A mildly enlarged pancreas with subtle hypoechogenicity is subjective and operator dependent. Conversely, a normal ultrasound does not exclude pancreatitis, particularly in mild disease. The corrective action is to treat imaging as one component of a probabilistic assessment, not as a binary test.

A fourth error is failing to screen for concurrent disease. Dogs with ehrlichiosis can have cPLI concentrations in the diagnostic range for pancreatitis without gastrointestinal signs, and the underlying infection requires different therapy. Endemic regions warrant serological screening in any dog with pancreatitis-like signs.

Evidence Limitations and Divergent Expert Opinion

The evidence base for canine pancreatitis diagnosis rests largely on retrospective studies and expert consensus instead of prospective trials. The ACVIM consensus statements provide structured guidance, but they also acknowledge that many recommendations are extrapolated from human medicine or based on low-quality veterinary data. The optimal cPLI decision threshold remains debated, with some experts favouring higher cut-offs to improve specificity at the cost of sensitivity.

The role of advanced imaging is similarly contested. Computed tomography is sensitive for pancreatic necrosis in humans, but its superiority over ultrasonography in dogs is not established, and availability and cost limit its use. Some specialists advocate early CT in severe cases, while others reserve it for suspected abscess or mass lesions. Both positions are defensible given the current evidence.

Nutritional timing is another area of divergence. Early enteral feeding is now widely recommended, but the optimal route, composition, and timing in dogs with refractory vomiting remain unclear. Expert opinion ranges from immediate naso-esophageal tube placement to a more cautious 24 hour fast with early reintroduction.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when a dog fails to improve within 48 to 72 hours of appropriate therapy, when complications such as acute kidney injury, respiratory distress, or coagulopathy develop, or when diagnostic uncertainty persists after cPLI and ultrasonography. Interventional radiology or surgery may be needed for pancreatic abscess, pseudocyst, or bile duct obstruction, and these cases should be transferred early instead of after deterioration.

Laboratory consultation is appropriate when results are discordant with clinical findings, when serial monitoring reveals unexplained trends, or when a reference interval question arises. The commercial laboratory can provide assay-specific guidance on sample handling and interpretation.

Regulatory reporting is rarely required for pancreatitis itself. However, if a dog develops pancreatitis in association with a drug or product suspected of being defective, the manufacturer and the relevant regulatory authority should be notified. The AVMA practice resources and the WOAH terrestrial animal health standards provide guidance on reportable disease obligations, though pancreatitis is not itself a reportable condition in most jurisdictions.

Troubleshooting Table

Frequently Asked Questions

How Should I Proceed When Abdominal Ultrasonography Is Not Available or Is Declined?

When ultrasonography is unavailable, the diagnosis rests on clinical signs, serum pancreatic lipase immunoreactivity, and exclusion of other causes of vomiting. Radiography can identify mechanical obstruction, foreign bodies, or loss of serosal detail, but it cannot confirm pancreatitis. If the clinical picture and laboratory findings strongly support pancreatitis, treatment can begin without imaging confirmation. Reassess the dog within 24 to 48 hours. If response to therapy is poor or deterioration occurs, referral for ultrasonography or advanced imaging should be pursued. The ACVIM consensus statements provide guidance on diagnostic standards when resources are limited.

What Does an Elevated Pancreatic Lipase Immunoreactivity Result Mean in a Dog with Concurrent Ehrlichiosis?

Serum canine pancreatic lipase immunoreactivity can be elevated in dogs with naturally occurring monocytic ehrlichiosis even in the absence of gastrointestinal signs. In one study, 20% of naturally infected dogs had concentrations in the diagnostic range for pancreatitis without showing vomiting or abdominal discomfort. This finding means a single elevated cPLI result in an endemic area does not confirm primary pancreatitis. Interpret the result alongside the complete blood count, platelet count, and serologic testing for tick-borne disease. If ehrlichiosis is confirmed, treat the infection and monitor pancreatic lipase after recovery. The MSD Veterinary Manual offers guidance on interpreting laboratory abnormalities in the context of infectious disease.

How Do I Explain the Diagnostic Uncertainty to an Owner Who Wants a Definite Answer?

Explain that pancreatitis is diagnosed by combining history, examination findings, blood tests, and imaging, and that no single test is perfect. Use the analogy of assembling pieces of evidence instead of finding one definitive marker. Describe what each test adds and what it cannot rule out. Be honest that some dogs with mild pancreatitis have normal blood results and that imaging changes may lag behind clinical signs. Outline the treatment plan and explain that response to therapy also supports the diagnosis. The AVMA practice resources include communication guidance for discussing diagnostic uncertainty with clients.

What Is the Role of Serum Amylase and Lipase Activity in the Current Diagnostic Workup?

Serum amylase and lipase activities are no longer recommended as primary diagnostic tests for canine pancreatitis. Both enzymes can be normal in confirmed pancreatitis and elevated in dogs with renal disease, gastrointestinal disease, or glucocorticoid administration. They lack the sensitivity and specificity needed for clinical decision-making. Pancreatic lipase immunoreactivity has replaced them as the preferred serum biomarker. If a practice laboratory only offers amylase and lipase, these results should be interpreted with caution and never used alone to confirm or exclude pancreatitis. The MSD Veterinary Manual summarizes the limitations of traditional enzyme assays in pancreatic disease.

When Should I Recommend Referral for Advanced Imaging Such as Computed Tomography?

Referral for computed tomography is appropriate when the diagnosis remains uncertain after ultrasonography, when pancreatic masses or abscesses are suspected, or when the dog fails to improve despite appropriate medical therapy. CT provides better assessment of pancreatic necrosis, peripancreatic fat stranding, and regional complications than ultrasonography in some cases. It also helps differentiate pancreatic neoplasia from inflammatory disease, although cytologic or histologic sampling may still be required. Discuss the cost and anesthetic risk with the owner before referral. The ACVIM consensus statements address the role of advanced imaging in complicated pancreatic disease.

How Should I Document the Diagnostic Workup and Treatment Response in the Medical Record?

Record the date and time of onset of vomiting, its frequency and character, and any precipitating events such as dietary indiscretion or medication administration. Document physical examination findings including abdominal palpation, hydration status, and body condition score. List each diagnostic test with its result and interpretation. For serial monitoring, record pain scores, vomiting episodes, appetite, and fluid balance at consistent intervals. Note any changes in therapy and the rationale for those changes. Include client communication summaries and planned recheck intervals. The AVMA practice resources provide guidance on medical record standards that support continuity of care and medicolegal defensibility.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Exocrine pancreatic neoplasia in the cat: a case series.. 2004.
• Feline exocrine pancreatic disorders.. 1999.
• Pancreatitis in cats: diagnosis and management of a challenging disease.. 2006.
• Clinical follow-up examination after treatment of canine leishmaniasis.. 1998.
• Serum canine pancreatic lipase immunoreactivity in experimentally induced and naturally occurring canine monocytic ehrlichiosis (Ehrlichia canis).. 2014.
• Analytical validation of an ELISA for the measurement of feline pancreas-specific lipase and re-evaluation of the reference interval and decision threshold for diagnosing pancreatitis.. 2023.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Vomiting: Diagnostic Approach and Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Vomiting: Diagnostic Approach for Cats
• Canine Lung Disease: Differential Diagnosis and Diagnostic Approach
• Canine Proteinuria: Diagnostic Approach and Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.